BR112016012505A2 - composto para tratamento de hipoglicemia severa - Google Patents

composto para tratamento de hipoglicemia severa

Info

Publication number
BR112016012505A2
BR112016012505A2 BR112016012505A BR112016012505A BR112016012505A2 BR 112016012505 A2 BR112016012505 A2 BR 112016012505A2 BR 112016012505 A BR112016012505 A BR 112016012505A BR 112016012505 A BR112016012505 A BR 112016012505A BR 112016012505 A2 BR112016012505 A2 BR 112016012505A2
Authority
BR
Brazil
Prior art keywords
treatment
compound
severe hypoglycaemia
hypoglycaemia
severe
Prior art date
Application number
BR112016012505A
Other languages
English (en)
Inventor
Alsina-Fernandez Jorge
Chadwick Cummins Robert
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52278803&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112016012505(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR112016012505A2 publication Critical patent/BR112016012505A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Removal Of Specific Substances (AREA)

Abstract

a presente invenção provê um novo composto útil no tratamento de hipoglicemia.
BR112016012505A 2013-12-18 2014-12-11 composto para tratamento de hipoglicemia severa BR112016012505A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361917658P 2013-12-18 2013-12-18
PCT/US2014/069646 WO2015094878A1 (en) 2013-12-18 2014-12-11 Novel compound for treatment of severe hypoglycemia

Publications (1)

Publication Number Publication Date
BR112016012505A2 true BR112016012505A2 (pt) 2017-09-26

Family

ID=52278803

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016012505A BR112016012505A2 (pt) 2013-12-18 2014-12-11 composto para tratamento de hipoglicemia severa

Country Status (26)

Country Link
US (1) US9688736B2 (pt)
EP (1) EP3083669A1 (pt)
JP (1) JP2017503782A (pt)
KR (1) KR20160077215A (pt)
CN (1) CN105793282A (pt)
AP (1) AP2016009268A0 (pt)
AR (1) AR098616A1 (pt)
AU (1) AU2014366427B2 (pt)
BR (1) BR112016012505A2 (pt)
CA (1) CA2928987A1 (pt)
CL (1) CL2016001473A1 (pt)
CR (1) CR20160223A (pt)
DO (1) DOP2016000128A (pt)
EA (1) EA201691036A1 (pt)
EC (1) ECSP16024805A (pt)
HK (1) HK1224303A1 (pt)
IL (1) IL245399A0 (pt)
MA (1) MA39108A1 (pt)
MX (1) MX2016007984A (pt)
NZ (1) NZ719451A (pt)
PE (1) PE20160787A1 (pt)
PH (1) PH12016501184A1 (pt)
SG (1) SG11201604232TA (pt)
TN (1) TN2016000180A1 (pt)
TW (1) TW201609129A (pt)
WO (1) WO2015094878A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
WO2019140024A1 (en) 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
EP3921336B1 (en) 2019-02-05 2023-03-01 Eli Lilly And Company Glucagon analog agonists and methods of using the same

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2124974B1 (en) * 2007-01-05 2017-03-15 Indiana University Research and Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
WO2009099763A1 (en) 2008-01-30 2009-08-13 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
KR20110039230A (ko) 2008-06-17 2011-04-15 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 생리학적 ｐＨ 완충액에서 강화된 용해도 및 안정성을 나타내는 글루카곤 유사체
EA019203B9 (ru) 2008-06-17 2014-03-31 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Коагонисты глюкагонового рецептора/glp-1-рецептора
TWI489992B (zh) 2008-12-19 2015-07-01 印地安那大學研究及技術公司 醯胺系胰高血糖素超級家族之胜肽前驅藥物
AU2010272944B2 (en) 2009-07-13 2015-11-19 Zealand Pharma A/S Acylated glucagon analogues
NZ601167A (en) 2010-01-20 2014-12-24 Zealand Pharma As Treatment of cardiac conditions
MX2012008603A (es) 2010-01-27 2013-01-25 Univ Indiana Res & Tech Corp Conjugados de antagonista de glucagon-agonista de gip y composiciones para el tratamiento de desordenes metabolicos y obesidad.
EP2552950A1 (en) * 2010-03-26 2013-02-06 Novo Nordisk A/S Novel glucagon analogues
US20130053310A1 (en) * 2010-03-26 2013-02-28 Novo Nordisk A/S Novel glucagon analogues
EP2568993A4 (en) 2010-05-13 2014-02-19 Univ Indiana Res & Tech Corp GLUCAGON SUPERFAMILY PEPTIDES EXPRESSING G PROTEIN-COUPLED RECEPTOR ACTIVITY
ES2661228T3 (es) 2010-05-13 2018-03-28 Indiana University Research And Technology Corporation Péptidos de la superfamilia de glucagón que muestran actividad de receptor nuclear de hormona
WO2011163012A2 (en) 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
EA201291234A1 (ru) 2010-06-24 2013-07-30 Зилэнд Фарма А/С Аналоги глюкагона
WO2011163473A1 (en) 2010-06-25 2011-12-29 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers
AR084558A1 (es) 2010-12-22 2013-05-22 Marcadia Biotech Metodos para tratar trastornos metabolicos y obesidad con peptidos basados en glucagon activos para el receptor de peptido insulinotropico dependiente de glucosa (gip)/peptido-1 similar al glucagon (glp-1)
BR112013018269A2 (pt) 2011-01-20 2017-06-06 Zealand Pharma As combinação de análogos acilados do glucagon com análogos da insulina
JP2014510739A (ja) * 2011-03-28 2014-05-01 ノヴォ ノルディスク アー／エス 新規のグルカゴン類似体
KR101968344B1 (ko) * 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물

Also Published As

Publication number Publication date
AR098616A1 (es) 2016-06-01
AP2016009268A0 (en) 2016-06-30
EP3083669A1 (en) 2016-10-26
PH12016501184A1 (en) 2016-07-25
US20160311883A1 (en) 2016-10-27
DOP2016000128A (es) 2016-06-30
SG11201604232TA (en) 2016-07-28
US9688736B2 (en) 2017-06-27
MA39108A1 (fr) 2017-11-30
JP2017503782A (ja) 2017-02-02
KR20160077215A (ko) 2016-07-01
CL2016001473A1 (es) 2017-03-10
ECSP16024805A (es) 2017-02-24
IL245399A0 (en) 2016-06-30
CN105793282A (zh) 2016-07-20
TW201609129A (zh) 2016-03-16
CA2928987A1 (en) 2015-06-25
HK1224303A1 (zh) 2017-08-18
MX2016007984A (es) 2016-09-09
WO2015094878A1 (en) 2015-06-25
AU2014366427A1 (en) 2016-05-19
AU2014366427B2 (en) 2017-02-16
EA201691036A1 (ru) 2016-12-30
NZ719451A (en) 2017-10-27
CR20160223A (es) 2016-07-12
PE20160787A1 (es) 2016-08-17
TN2016000180A1 (en) 2017-10-06

Similar Documents

Publication Publication Date Title
CL2018000429A1 (es) Moduladores de la expresión de kras
UY35821A (es) Compuesto heterocíclico
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
EP2970161B8 (en) Gpr120 agonists for the treatment of type ii diabetes
BR112017008481A2 (pt) composto antimicótico
EA201790312A1 (ru) Комбинации лекарственных средств для лечения множественной миеломы
MX366636B (es) Nuevo derivado de un análogo de insulina.
AR097668A1 (es) Colorante-polímero
UY34575A (es) Composiciones y métodos para el tratamiento de diabetes y/u obesidad
MX2015008829A (es) Momelotinib deuterado.
DOP2016000142A (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
BR112016012505A2 (pt) composto para tratamento de hipoglicemia severa
ECSP16024798A (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
MX2015012610A (es) Pacritinib deuterizado.
EA201690709A1 (ru) Применение одипарцила в лечении мукополисахаридоза
ES1078913Y (es) Dispositivo de avance mandibular combinado con depresion lingual para el tratamiento del ronquido.
TH1501002638A (th) รูปแบบยาที่มีการปลดปล่อยยาแบบออกฤทธิ์เนิ่นของรูโซลิทินิบ
CL2012000641S1 (es) Lavamanos.
CL2011001917A1 (es) Uso de ezatiostat o una sal de el para el tratamiento del sindrome mielodisplasico.
TN2011000372A1 (fr) جهاز مراقبة وتحكم في استهلاك المياه

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2544 DE 08-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]